The Europe idiopathic pulmonary fibrosis treatment market size reached US$ 553 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 892 Million by 2028, exhibiting a growth rate (CAGR) of 8.3% during 2023-2028. More Info:- https://www.imarcgroup.com/europe-idiopathic-pulmonary-fibrosis-treatment-market

1. Copyright © IMARC Service Pvt Ltd. All Rights Reserved
Europe Idiopathic Pulmonary
Fibrosis Treatment Market Research
and Forecast Report 2023-2028
Author: Elena Anderson
Marketing Manager
IMARC Group
© 2022 IMARC All Rights Reserved

2. Report Description
About IMARC Group
International Market Analysis Research and Consulting Group is a leading adviser on
management strategy and market research worldwide. We partner with clients in all regions
and industry verticals to identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.

3. Report Description
Report Description and Highlights
Europe Idiopathic Pulmonary Fibrosis Treatment Market Research Report 2023-2028:
According to the latest report by IMARC Group, titled " Europe Idiopathic Pulmonary Fibrosis
Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,"
the Europe idiopathic pulmonary fibrosis treatment market size reached US$ 553 Million in 2022.
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial pneumonia that severely
impacts the functioning of the lungs. It forms scar tissue within the lungs that starts at the edges and
develops toward the center, thus causing insufficient oxygen delivery to body parts. It is diagnosed
through various chest imaging studies, including pulmonary function tests, lung biopsies, and
antibody tests.
Moreover, this condition is treated with antifibrotic therapies, including nintedanib and pirfenidone-
based drugs, that improve lung functioning and minimize the risks of respiratory deterioration. In
recent years, there has been an escalating demand for IPF treatment procedures due to the growing
prevalence of lung disorders.
Request for a PDF sample of this report: https://www.imarcgroup.com/europe-idiopathic-
pulmonary-fibrosis-treatment-market/requestsample

4. Report Description
Report Description and Highlights
Europe Idiopathic Pulmonary Fibrosis Treatment Market Trends:
The market is primarily driven by the growing prevalence of chronic lung and fibrotic diseases in Europe.
In addition, the growing geriatric population that is more susceptible to such ailments represents
another major growth-inducing factor. Besides this, the changing living standards, high smoking rates,
and increasing environmental pollutants are causing various lung diseases among individuals. This,
coupled with the increasing health consciousness and growing awareness regarding the presence of
effective IPF preventive and management treatment, is positively influencing the market growth.
Moreover, the market is further propelled by the increasing government investments in developing
existing healthcare systems. Furthermore, rapid advancements in diagnostic techniques and research
and development (R&D) activities conducted by the leading players for introducing novel medicines are
also creating a positive market outlook across the region.
View Report TOC, Figures and Tables: https://www.imarcgroup.com/europe-idiopathic-pulmonary-
fibrosis-treatment-market

5. Report Description
Report Description and Highlights
Key Market Segmentation
The research report includes the following segments:
Breakup by Drug Class:
•MAPK Inhibitors
•Tyrosine Inhibitors
•Autotaxin Inhibitors
Breakup by End User:
•Hospitals
•Long-term Care Facilities
•Others
Breakup by Country:
•Germany
•France
•United Kingdom
•Italy
•Spain
•Others

6. Report Description
Key Questions Answered in the Report
1. How big is the Europe idiopathic pulmonary fibrosis treatment market?
2. What is the expected growth rate of the Europe idiopathic pulmonary fibrosis treatment market
during 2023-2028?
3. What are the key factors driving the Europe idiopathic pulmonary fibrosis treatment market?
4. What has been the impact of COVID-19 on the Europe idiopathic pulmonary fibrosis treatment
market?
5. What is the breakup of the Europe idiopathic pulmonary fibrosis treatment market based on the
drug class?
6. What is the breakup of the Europe idiopathic pulmonary fibrosis treatment market based on the
end user?
7. What are the key regions in the Europe idiopathic pulmonary fibrosis treatment market?

7. Report Description Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Europe Idiopathic Pulmonary Fibrosis Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

8. Report Description Table of Contents
6 Market Breakup by Drug Class
6.1 MAPK Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Tyrosine Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Autotaxin Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by End User
7.1 Hospitals
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Long-term Care Facilities
7.2.1 Market Trends
7.2.2 Market Forecast
Click here to visit the complete table of content with list of figures and tables:
https://www.imarcgroup.com/europe-idiopathic-pulmonary-fibrosis-treatment-market/toc

9. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

10. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

11. Report Description
Report Description and Highlights
© 2022 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of
International Market Analysis Research and Consulting (IMARC). No part of this publication may be
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be
used in any form or by and means graphic electronic or mechanical, including photocopying, recording,
taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been
based on information and sources believed to be accurate and reliable at the time of publishing.
International Market Analysis Research and Consulting makes no representation of warranty of any kind as to
the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any
loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market
Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of
their respective companies.

12. FOR MORE DETAILS
Visit us at :
Stay With Us:
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com
https://www.imarcgroup.com
Contact Us